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Bullet points: 
What’s already known about this topic? 
 Female sex hormones have been suggested to play a role in the etiology of 
cutaneous melanoma (CM) and some epidemiological studies suggest that estrogen 
increase the risk of CM.  
 The association with endogenous sex hormones have been studied through various 
reproductive factors, and parity, age at menarche, age at first birth and length of 
ovulatory life have been found to be associated with the risk of CM. 
 
What does this study add? 
 In this large nationwide population-based study of the association between 
reproductive factors and CM risk with detailed exposure and confounder 
information, no reproductive factors were clearly associated with CM risk. 
 Association between reproductive factors and histological subtypes and anatomical 
sites are scarcely described in the literature. We observed significant heterogeneity 
in the effect of length of ovulatory life on the risk of superficial spreading melanoma 
and nodular melanoma. 
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Summary 
Background  
The association between reproductive factors and risk of cutaneous melanoma (CM) is unclear. We 
investigated this issue in the Norwegian Women and Cancer (NOWAC) cohort study. 
 
Objectives 
To examine the association between the reproductive factors age at menarche, menstrual cycle 
length, parity, age at first and last birth, menopausal status, breastfeeding duration and length of 
ovulatory life and CM risk, overall and by histological subtypes and anatomical site 
 
Methods 
We followed 165,712 women aged 30-75 at inclusion from 1991-2007 to the end of 2015. 
Multivariable Cox regression was used to estimate hazard ratios (HRs) with 95% confidence intervals 
(CIs).  
 
Results 
The mean age at cohort enrolment was 49 years. During a median follow-up of 18 years, 1,347 CM 
cases were identified. No reproductive factors were clearly associated with CM risk. When stratifying 
by histological subtype we observed significant heterogeneity (p = 0.01) in the effect of length of 
ovulatory life on the risk of superficial spreading melanoma (HR 1.02, 95% CI 1.01-1.04 per year 
increase) and nodular melanoma (HR 0.97, 95% CI 0.94-1.01 per year increase). When stratifying by 
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anatomical site, menopausal status (HR 0.54, 95% CI 0.31-0.92, postmenopausal compared to 
premenopausal) and menstrual cycle length (HR 1.07, 95% CI 1.01-1.13, per day increase) were 
associated with CM of the trunk, and significant heterogeneity between anatomical sites was 
observed for menopausal status (p = 0.04).   
 
Conclusions  
In this large population-based Norwegian cohort study, we did not find convincing evidence of an 
association between reproductive factors and risk of CM. 
 
Introduction 
The incidence of cutaneous melanoma (CM) is rising in Caucasian populations, despite recent 
improvements in prevention and diagnosis (1). In 2012 CM was estimated to account for 232,000 
new cancer cases and 55,000 deaths worldwide (2).  
Exposure to solar ultraviolet (UV) radiation and indoor tanning, having a fair skin complexion, 
presence of many nevi and freckles, light hair, and skin reaction to the sun are important CM risk 
factors(3, 4). Female sex hormones, both endogenous and exogenous, have also been suggested to 
play a role in the etiology of CM. The fact that a better CM prognosis is observed in females than in 
males, and that the incidence of CM is higher among women than men between the age of 20 and 
45 years, but that an opposite trend is observed after the age of 50 suggests that female sex 
hormones might influence CM development and prognosis (5, 6). The association between female 
sex hormones and risk of CM is biologically plausible as both estrogen receptors α, β and the non-
standard G protein-coupled estrogen receptor, as well as progesterone receptors, are found in CM 
tissue (7, 8). Some in vitro experiments suggested that estrogen might increase proliferation of 
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melanocytes and CM cells, while progesterone possibly acts as an anti-proliferative and pro-
apoptotic agent (8-12).   
A large Dutch case-control study found a strong detrimental effect of oral contraceptives (OC) and 
unopposed estrogen hormone therapy (HT) on CM risk (13). In a large cohort study from Norway on 
HT, estrogen was positively associated with CM risk, while progestin seemed to be protective of CM 
(14). However, a meta-analysis of epidemiological studies up to 2009 found no association between 
HT or OC and CM risk (15). The meta-analysis did, however, find age at first birth to be positively 
associated with CM risk (i.e. the older the age the higher the risk), and parity to be inversely 
associated with CM risk. Additionally, did and a large Swedish case-control study report both parity 
and early childbearing to be protective of CM, although personal UV exposure was not adjusted for 
(16). A large French cohort study from 2011 found late age at menarche, early natural menopause 
and shorter ovulatory life to be associated with lower risk of CM (17).   
Overall, the association between female sex hormones and CM risk is still controversial, and there 
has been little focus on hormones in relation to CM histological subtypes and anatomical sites 
relating to the divergent pathways hypothesis (18). We studied the association between the 
reproductive factors age at menarche, menstrual cycle length, parity, age at first and last birth, 
menopausal status, breastfeeding duration and length of ovulatory life, and risk of CM overall and by 
histological subtype and anatomical site in a large nationwide population-based cohort.  
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Material and methods 
Data source 
The Norwegian Women and Cancer (NOWAC) cohort was established in 1991 as a large nationwide 
population-based cohort in Norway. Cohort characteristics of NOWAC have been described in detail 
elsewhere (19). Briefly, invitation letters were sent to random samples of in total 327,476 women 
aged 30-75 in 1991-2007 with a response rate of 53%. Women who answered the baseline 
questionnaire were sent follow-up questionnaires every 4-6 years (response 80% for the second and 
79% for third questionnaire).  Follow-up was evaluated by linkage to the Cancer Registry of Norway 
for information on cancer diagnosis and vital status. 
In total, we included 172,478 women answering the baseline questionnaire. We excluded women 
with a cancer diagnosis other than non-melanoma skin cancer prior to inclusion (n=6,694) and date 
of death or emigration prior to inclusion (n=72), resulting in a final sample size of n=165,712 (Fig. 1).  
 
Exposure and outcome  
Participants were asked about their reproductive history in the baseline and follow-up 
questionnaires. The exposures of interest were age at menarche (≤11, 12, 13, 14 or ≥15 years), 
menstrual cycle length during midlife defined as number of days between the first day of 
menstruating in two consecutive cycles  (<25, 25-30 or >30 days), parity (including stillbirths) (0, 1, 2, 
3 or ≥4 children), age at first birth (<22, 22-23, 24-26 or ≥27 years), age at last birth (<26, 26-28, 29-
32 or ≥33 years), total breastfeeding duration (0, 1-4, 5-9, 10-16 or ≥17 months) and menopausal 
status (premenopausal, postmenopausal), defined based on the question “How old were you when 
the menstruation ceased?”. Women with missing information on age at menopause (37%) were 
coded as menopausal at age 53, which is the cutoff used in the Million Women Study (20) and the 
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validity has been demonstrated in a previous NOWAC publication (21).  Length of ovulatory life was 
calculated as the age difference between menopause and menarche subtracting 9 months for each 
pregnancy, and categorized according to quartiles. 
The outcome was incident CM using the Cancer Registry of Norway modified version of the 
International Classification of Diseases 7th revision (ICD-7 codes 1900-1909). Anatomical site was 
defined as head/neck (190.0), trunk (190.1/190.7), upper limbs (190.2) and lower limbs 
(190.3/190.4). Histological subtype was defined using ICD-Oncology 3rd edition codes (superficial 
spreading melanoma (SSM) = 8743.3 and nodular melanoma (NM) = 8721.3; other subtypes were 
too rare to be included). 
 
Covariates 
Region (latitudes 71○N – 58○N) of residential ambient UV exposure was categorized according to 
average number of hours of ambient residential UV exposure (low (northern Norway), medium-low 
(central Norway), medium (southwestern Norway), highest (southeastern Norway) (22). Birth cohort 
was categorized in 5-years intervals (<1940, 1940-1944, 1945-1949 and ≥1950). Body surface area 
(BSA) (m2) was calculated using the DuBois and DuBois’ equation (weight0.4253 x height0.7253 x 
0.007184) and categorized according to quartiles (23). We categorized smoking as (never, past or 
current), education (≤10, 11-13 or >13 years) and marital status (married/partnered or not 
married/partnered) at cohort enrolment (baseline). Host pigmentation included untanned skin color 
(recorded on an 1 x 9 cm color scale graded from 1 (very fair) to 10 (very dark); categorized as dark 
(6-10), medium (4 and 5) or light (1-3)), hair color (black/dark brown, brown, blond/yellow or red) 
and number of asymmetric nevi >5 millimeters on legs (0, 1 or ≥2). Lifetime UV exposure until cohort 
enrolment included mean number of sunburns per year (0, ≤1, 1-2 or >2), mean number of weeks 
per year spent on sunbathing vacation (0, ≤1, 1-2, 2-3 or >3), and use of indoor tanning devices 
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(never, age at initiation <30 years or age at initiation ≥30 years). These were calculated according to 
Ghiasvand et al. (24, 25).  None of the exposures were adjusted for use of OC or HT, as adjusting for 
this did not change the estimated associations.  
 
Statistical analysis 
Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated by Cox regression using age 
as time scale and left truncated at age of first questionnaire. Diagnosis of CM was the event of 
interest. Women were censored at death, emigration, cancer diagnosis other than CM, except non-
melanoma skin cancer, or end of follow-up (December 31, 2015), whichever occurred first.  
Parity and menopausal status were analyzed as time-dependent variables. Age at last birth, duration 
of breastfeeding and length of ovulatory life were only analyzed among postmenopausal women, 
starting follow-up at age of menopause. When analyzing age at first and last birth only parous 
women were included.  
All estimates were adjusted for residential ambient UV exposure, birth cohort, host pigmentation 
(hair color, skin color and large asymmetric nevi) and personal UV exposure (sunburns, bathing 
vacations and indoor tanning). Additional potential adjustment variables were selected based on 
simplified directed acyclic graphs for each exposure, and only variables that significantly improved 
the fit of the model were included. 
When analyzing the association of reproductive factors by anatomical site only CM diagnosis at that 
specific site was analyzed as event, while CM in other sites were considered as censoring events. We 
did the same for histological subtypes. Heterogeneity between histological subtypes and anatomical 
sites was evaluated by contrast tests (26). 
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We performed sensitivity analysis, excluding women with very dark skin (grades 8-10). We also 
adjusted for birth cohort by stratification (stratified Cox-regression) instead of regular adjustment. In 
a subgroup of women with available information on use of OC we subtracted years of OC use from 
the length of ovulatory life measure.  
The exposures of interest and covariates had a varying degree of missing values (0 – 70%), see 
Supplementary table 1 and 2 for details. To assess the influence of missing values we used multiple 
imputation with chained equations, assuming that the missing values are missing at random (27). 
The imputation model included the outcome and all exposures and adjustment variables. We 
imputed 70 data sets and the estimates and standard errors were combined using Rubin’s rules (28).   
 All tests were two sided with a 5% statistical significance level. Proportionality was assessed with 
Schoenfeld residuals. All statistical analyses were performed using R version 3.3.3 (http://cran.r-
project.org) and the R-package mice, version 2.46.0 was used for multiple imputation (29).  
 
Ethics 
NOWAC has been approved by the Regional Committees for Medical and Health Research and the 
Norwegian Data Inspectorate. All participants have given written consent. 
 
Results 
We followed 165,712 women from cohort enrolment in 1991-2007 to the end of 2015. The median 
follow-up was 18.1 years (range <1 to 24.7 years) during which 1,347 incident CM occurred. 
Characteristics of CM cases and non-cases are described in Table 1.  
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The risks of CM associated with reproductive factors are reported in Table 2. Menarche at age 12 
was significantly associated with an increased risk of CM compared to age 13 (HR 1.18, 95% CI 1.02-
1.38), but no trend emerged. Menstrual cycle length during midlife, parity, age at first birth, 
menopausal status, age at last birth and breastfeeding duration were not significantly associated 
with CM risk. 
When separating CM into SSM and NM, significant heterogeneity was found for length of ovulatory 
life (p=0.01) (Table 3). Length of ovulatory life was significantly positively associated with SSM (HR 
1.02, 95% CI 1.00-1.04, per year increase) and not associated with NM (HR 0.97, 95% CI 0.94-1.01).  
Table 4 displays the anatomical site-specific results for the reproductive factors. Significant 
heterogeneity was observed for menopausal status (p=0.04). Postmenopausal women had a 
significantly lower risk of CM of the trunk (HR 0.54, 95% CI 0.31-0.92) as compared to 
premenopausal women. In addition, menstrual cycle length during midlife was associated with a 
significantly increased risk of CM of the trunk (HR 1.07, 95% CI 1.01-1.13, per year increase), but with 
no significant heterogeneity between sites (p=0.07).  
As a sensitivity analysis we excluded women with very dark skin (n=2,491) and the results did not 
change substantially (data not shown). Additionally, when adjusting for birth cohort by stratification 
the results were similar as with regular adjustment (data not shown). When analyzing length of 
ovulatory life calculated as the age difference between menopause and menarche subtracting 9 
months for each pregnancy and years of OC use in the subset of women with available OC 
information, the results were similar to the analyses with years of OC use not subtracted (data not 
shown). Multiple imputation generally resulted in very similar estimates to the main analyses (data 
not shown), but some discrepancies were observed. In particular, the association between 
menstrual cycle length and CM of the trunk was no longer statistically significant (HR 1.02, 95% CI 
0.99-1.04 per year increase). 
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Discussion 
In this nationwide population-based cohort we evaluated the association between several 
reproductive factors and CM risk. Our results suggest that reproductive factors are not associated 
with CM risk. However, we observed some heterogeneity between CM histological subtypes and 
between anatomical sites. Each year increase in length of ovulatory life was significantly associated 
with a 2% increased risk of SSM, and postmenopausal women were at significantly lower risk of CM 
of the trunk as compared to premenopausal women.  
A number of epidemiological studies have evaluated the association between exogenous female sex 
hormones and CM, but the associations with use of menopausal hormone therapy (HT) and with oral 
contraceptives (OC) are still controversial. A large meta-analysis comprising six cohort studies and 19 
case-control studies published up to 2009 found no significant associations between either HT or OC 
(15), and three newer studies found no association (30), an increased risk of HT estrogen and 
decreased risk of HT progestin (14) and a protective effect of HT/OC use (31), respectively. 
Endogenous female sex hormones have been evaluated in a number of epidemiological studies 
through reproductive factors. The meta-analysis of studies published up to 2009 reported an 
increased risk of melanoma in women with late age at first birth, but no association with 
menopausal status, age at menopause, age at menarche, exams for fertility or parity (15). A newer 
meta-analysis comprising three case-control, three nested case-control and five cohort studies 
published up to 2014 reported a pooled relative risk of 1.47 (95% CI 1.07-2.02) comparing oldest to 
youngest age at first birth (32). Although there seem to be an association between age at first birth 
and CM risk, which is in contrast to our null finding, the hormonal mechanism is questionable as 
Kaae et al. found similar estimates for age at first birth in males and females in a large Danish study 
comprising 5,688 CM cases, and suggested life-style factors to be a more likely explanation (33).  
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In accordance with the meta-analysis of studies published up to 2009 we did not find a convincing 
association with age at menarche (15). However, Kvaskoff et al. reported a significantly reduced risk 
of CM in women with later age at menarche, and shorter length of ovulatory life (17). The latter is, 
however, in line with our non-significant association of 1% increase per 1 year increase in ovulatory 
life. Our measure of length of ovulatory life did not account for use of OC, however in the sensitivity 
analysis with years of OC use subtracted from length of ovulatory life, the result was similar. 
The associations between reproductive factors and CM histology and site are scarcely described in 
the literature. Kvaskoff et al. reported mainly comparable estimates across CM histology (17). This is 
in contrast to our findings of opposite associations of length of ovulatory life for SSM and NM, but 
the number of cases within each histology in Kvaskoff et al. was very low and our estimates are close 
to 1 and only borderline significant for SMM. Kvaskoff et al. noted a significant heterogeneity for 
nulliparity between head/neck and trunk, although the individual estimates were not statistically 
significant. Our results indicate a similar opposite association for head/neck (HR 0.51, 95% CI 0.22-
1.16) and trunk (HR 1.14, 0.95% CI 0.85-1.54), but with no significant heterogeneity (p=0.07). We 
found significant heterogeneity across CM sites for menopausal status, which was not observed in 
Kvaskoff et al. This heterogeneity may be due to residual confounding by age as CM on the trunk 
tend to occur at earlier ages, especially in women (34).  
The association between sex hormones and risk of CM is biologically plausible, but the mechanisms 
through which they exert they effect are still largely unknown. In-vitro experiments have suggested 
that estrogen might increase proliferation of melanocytes and CM cells, while progesterone possibly 
acts as an anti-proliferative and pro-apoptotic agent, counteracting the stimulatory effect of 
estrogen (8-12), which might explain the large amount of null-findings in the literature. Another 
possible mechanism is through telomere length, where longer telomeres have been found to 
increase the risk of melanoma (35, 36). Estrogen upregulates telomerase in in-vitro experiments, and 
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longer ovulatory life and higher parity have been found to respectively increase and decrease 
telomere length (37-39).  
The major strengths of this study are the representative, nationwide population-based prospective 
design with a follow-up of up to 25 years, the detailed covariate information and the accurate 
outcome information through linkage with high quality national registries. The design of the study 
allows for generalizability of findings to the whole country, and perhaps broader.  The major 
limitation is that all covariates are self-reported, thus some misclassification is likely to have 
occurred, but it was most probably non-differential, since all the information was collected before 
CM diagnosis. We have not adjusted for multiple testing, but it is clear that none of the estimates in 
the sub analyses, nor the heterogeneity tests, would continue to be significant.  
In conclusion, no reproductive factor was clearly associated with CM risk in this nationwide cohort 
study. 
 
Acknowledgements: We are grateful to the women who participated in the NOWAC study.  
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Figure legends 
Figure 1. Flowchart of study participants: The NOWAC Study. 
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Table 1. Baseline characteristics of the study participants and association with melanoma risk: The 
NOWAC Study.  
 Incident melanoma 
 Yes  
N (%) 
No  
N (%) 
Age in yearsa 48 (43, 56) 49 (43, 56) 
Birth cohort, n = 165 712   
  < 1940 137 (10) 14 458 (9) 
  1940 – 1944 234 (17) 20 605 (13) 
  1945 – 1949 408 (30) 47 248 (29) 
  ≥ 1950 568 (42) 82 054 (50) 
Education, n = 157 008   
   ≤ 10 years 412 (32) 55 733 (36) 
  11-13 years 416 (33) 45 990 (30) 
  > 13 years 448 (35) 54 009 (35) 
Marital status, n= 160 129   
  Married/partnered 1 056 (81) 126 253 (79) 
  Not married/partnered 247 (19) 32 573 (21) 
Smoking status, n= 164 914   
  Never 576 (43) 57 772 (35) 
  Past 456 (34) 56 084 (34) 
  Current 305 (23) 49 721 (30) 
Body surface area, 161 590   
  Q1: < 1.65 m2 282 (21) 39 933 (25) 
  Q2: 1.65 – 1.73 m2 324 (25) 40 148 (25) 
  Q3: 1.74 – 1.83 m2 385 (29) 40 000 (25) 
  Q4: ≥ 1.83 m2 324 (25) 40 194 (25) 
Hair color, n = 151 700   
  Black/dark brown 137 (11) 26 231 (17) 
  Brown 382 (31) 60 404 (40) 
  Blond/yellow 623 (51) 59 193 (39) 
  Red 88 (7) 4 642 (3) 
Skin color, n = 131 261   
  Very dark/dark  189 (18) 28 325 (22) 
  Medium 379 (35) 49 181 (38) 
  Light 503 (47) 52 684 (40) 
Total no. of asymmetrical nevi with diameter >5 
mm on legs, n = 145 641 
  
  0 891 (76) 127 617 (88) 
  1 126 11) 9 713 (7) 
  ≥ 2 154 (13) 7 140 (5) 
Residential ambient UV exposure n = 165 712   
  Low (northern Norway) 144 (11) 35 788 (22) 
  Medium-low (central Norway) 161 (12) 18 426 (11) 
  Medium(southwestern Norway) 279 (21) 30 562 (19) 
  Highest (southeastern Norway) 763 (57) 79 589 (48) 
Mean sunburns per year,  n = 122 083    
  0 90 (9) 17 744 (15) 
  ≤ 1 612 (60) 74 975 (62) 
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  > 1 – 2 230(22) 21 280 (18) 
  > 2 93 (9) 7 059 (6) 
Mean weeks of sunbathing vacations per year,  
n = 130 723  
  
  0 129 (12)  16 713 (13) 
  ≤ 1 300 (28) 38 454 (30) 
  > 1 – 2 352 (33) 42 475 (33) 
  > 2 – 3 157 (15) 18 760 (14) 
  > 3 136 (13) 13 247 (10) 
Indoor tanning, n = 131  135   
  Never  381 (35) 45 129 (35) 
  Age at initiation < 30 years 160 (15) 20 790 (16) 
  Age at initiation ≥ 30 years 555 (51) 64 120 (49) 
aMedian (interquartile range. 
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Table 2. Reproductive factors and risk of melanoma: The NOWAC Study. 
 No. of cases Person years HRa (95% CI) 
Age at menarche, n = 162,881    
  ≤ 11 years 99 234,772 0.87 (0.70 – 1.09) 
  12 years 295 514,209 1.18 (1.02 – 1.38) 
  13 years 368 749,315 Ref. 
  14 years 326 665,886 0.97 (0.84 – 1.13) 
  ≥ 15 years 236 483,364 0.94 (0.80 – 1.11) 
  Per year 1324  0.98 (0.94  - 1.02) 
Menstrual cycle length during midlifeb, 
n = 47,880 
   
  < 25 days 63 141,304 0.96 (0.74 – 1.26) 
  25 – 30 days 421 896,872 Ref. 
  > 30 days 20 49,273 0.86 (0.55 – 1.35) 
  Per day 504  1.01 (0.98 – 1.04) 
Parityc,i, n = 165,712    
  0 children 127 248,316 Ref. 
  1 child 134 312,595 0.90 (0.70 – 1.14) 
  2 children 580 1,123,020 1.06 (0.88 – 1.29) 
  3 children 366 707,996 1.11 (0.91 – 1.37) 
  ≥ 4 children 140 302,388 1.04 (0.81 – 1.33) 
Per child 1347  1.03 (0.98 – 1.08) 
Nulliparousc,i, n = 165,712    
  No 1220 2,445,998 Ref. 
  Yes 127 248,316 0.95 (0.79 – 1.14) 
Age at first birthc,f, n = 149,863    
  < 22 years 373 805,770 Ref. 
  22 – 23 years 234 474,191 0.96 (0.81 – 1.13) 
  24 – 26 years 310 571,500 1.00 (0.86 – 1.17) 
  ≥ 27 years 303 594,450 0.94 (0.80 – 1.11) 
Per year 1220  0.99 (0.98 – 1.01) 
Menopausal statusd,i, n = 165,712    
  Pre 226 752,486 Ref. 
  Post 1,120 1,938,493 0.83 (0.62 – 1.13) 
Age at last birthc,h, n = 127,350    
  < 26 years 235 406,030 Ref. 
  26 – 28 years 223 372,334 0.97 (0.81 – 1.17) 
  29 – 32 years 282 480,843 0.94 (0.79 – 1.12) 
  ≥ 33 years 274 504,874 0.88 (0.73 – 1.06) 
  Per year 1013  0.99 (0.98 – 1.00) 
Breastfeeding duratione,g, n = 85,406    
  0 months 49 77,782 1.17 (0.85 – 1.62) 
  1 – 4 months 101 213,166 0.93 (0.72 – 1.20) 
  5 – 9 months 145 279,902 Ref. 
  10 – 16 months 165 274,857 1.14 (0.91 – 1.42) 
 ≥17 months 194 340,141 1.07 (0.86 – 1.33) 
 Per month 654  1.00 (0.99 – 1.01) 
Length of ovulatory lifeb,g, n = 142,611    
  Q1: < 33.5 years 267 457,714 0.95 (0.80 – 1.12) 
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  Q2: 33.5 – 36.5 years 268 531,090 Ref. 
  Q3: 36.6 – 38.4 years 224 378,113 0.99 (0.83 – 1.19) 
  Q4: ≥ 38.5 years 212 349,846 1.03 (0.86 – 1.24) 
  Per year 971  1.01 (0.99 – 1.02) 
aHazard ratios (HRs) and 95% confidence intervals (CIs)  from Cox regression with age as the time 
scale (age adjusted) and adjusted for residential ambient ultraviolet (UV) exposure, birth cohort, 
host pigmentation (hair color, skin color and large asymmetric nevi) and UV exposure (sunburns, 
bathing vacations and solarium use). bAdditionally adjusted for body surface area (BSA) and smoking. 
cAdditionally adjusted for education. dAdditionally adjusted for BSA, smoking and education. 
eAdditionally adjusted for marital status and smoking. fOnly in parous women. gOnly in 
postmenopausal women. hOnly in parous postmenopausal women. iAnalysed as time-dependent.  
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Table 3. Reproductive factors and risk of melanoma by histological subtype: The NOWAC Study. 
 Superficial spreading 
melanoma 
 
Nodular melanoma 
 
 No. of 
cases 
HRa (95% CI) No. of 
cases 
HRa (95% CI) p for heterogeneity 
Age at menarche, n = 162,881      
 
  ≤ 11 years 58 0.86 (0.65 – 1.16) 17 1.01 (0.59 – 1.75)  
  12 years 190 1.30 (1.07 – 1.58) 38 1.02 (0.68 – 1.54)  
  13 years 215 Ref. 55 Ref.  
  14 years 199 1.03 (0.85 – 1.25) 43 0.85 (0.57 – 1.27)  
  ≥ 15 years 144 1.01 (0.81 – 1.24) 36 0.93 (0.61 – 1.42)  
  Per year 806 0.98 (0.93 – 1.03) 189 0.96 (0.87 – 1.07) 0.76 
Menstrual cycle length during midlifeb, 
n = 47,880 
     
  < 25 days 35 0.86 (0.60 – 1.22) 10 1.01 (0.52 – 1.97)  
  25 – 30 days 264 Ref. 62 Ref.  
  > 30 days 14 0.96 (0.56 – 1.63) 4 1.20 (0.43 – 3.30)  
  Per day 313 1.02 (0.99 – 1.07) 76 1.04 (0.96 – 1.13) 0.77 
Parityc,i, n = 165,712      
  0 children 80 Ref. 19 Ref.  
  1 child 84 0.88 (0.65 – 1.19) 10 0.46 (0.21 – 0.99)  
  2 children 357 1.03 (0.81 – 1.31) 93 1.19 (0.73 – 1.96)  
  3 children 208 1.02 (0.79 – 1.32) 48 0.98 (0.57 – 1.67)  
  ≥ 4 children 92 1.16 (0.86 – 1.58) 21 0.92 (0.49 – 1.74)  
Per child 821 1.04 (0.98 – 1.10) 191 1.02 (0.90 – 1.14) 0.73 
Nulliparousc,i, n = 165,712      
  No 741 Ref. 172 Ref.  
  Yes 80 0.98 (0.78 – 1.24) 19 1.00 (0.62 – 1.61) 0.95 
Age at first birthc,f, n = 149,863      
  < 22 years 222 Ref. 54 Ref.  
  22 – 23 years 152 1.05 (0.85 – 1.29) 30 0.89 (0.57 – 1.40)  
  24 – 26 years 189 1.02 (0.83 – 1.25) 45 1.09 (0.72 – 1.65)  
  ≥ 27 years 178 0.92 (0.74 – 1.13) 43 1.03 (0.67 – 1.59)  
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Per year 741 0.99 (0.98 – 1.01) 172 0.99 (0.96 – 1.03) 0.96 
Menopausal statusd,i, n = 165,712      
  Pre 164  26 Ref.  
  Post 656 0.72 (0.49 – 1.06) 165 1.22 (0.54 – 2.78) 0.25 
Age at last birthc,h, n = 127,350      
  < 26 years 136 Ref. 34 Ref.  
  26 – 28 years 128 0.98 (0.77 – 1.25) 37 1.10 (0.69 - 1.77)  
  29 – 32 years 158 0.93 (0.74 – 1.18) 44 1.01 (0.64 – 1.59)  
  ≥ 33 years 169 0.98 (0.77 – 1.24) 32 0.70 (0.42 – 1.16)  
  Per year 591 1.00 (0.98 – 1.02) 147 0.98 (0.94 – 1.01) 0.24 
Breastfeeding duratione,g, n = 85,406      
  0 months 29 1.28 (0.83 – 1.96) 8 1.15 (0.51 – 2.56)  
  1 – 4 months 61 1.02 (0.73 – 1.43) 15 0.84 (0.44 – 1.60)  
  5 – 9 months 79 Ref. 24 Ref.  
  10 – 16 months 91 1.15 (0.85 – 1.55) 27 1.15 (0.66 – 1.99)  
 ≥17 months 110 1.11 (0.83 – 1.49) 28 0.98 (0.56 – 1.70)  
 Per month 370 1.00 (0.99 – 1.01) 102 1.00 (0.98 – 1.01) 0.69 
Length of ovulatory lifeb,g, n = 142,611      
  Q1: < 33.5 years 138 0.80 (0.63 – 1.01) 53 1.34 (0.87 – 2.08)  
  Q2: 33.5 – 36.5 years 162 Ref. 35 Ref.  
  Q3: 36.6 – 38.4 years 131 0.95 (0.75 – 1.19) 35 1.20 (0.75 – 1.93)  
  Q4: ≥ 38.5 years 130 1.03 (0.81 – 1.30) 23 0.87 (0.51 – 1.49)  
  Per year 561 1.02 (1.00 – 1.04) 146 0.97 (0.94 – 1.01) 0.01 
aHazard ratios (HRs) and 95% confidence intervals (CIs)  from Cox regression with age as the time scale (age adjusted) and adjusted for residential ambient 
ultraviolet (UV) exposure, birth cohort, host pigmentation (hair color, skin color and large asymmetric nevi) and UV exposure (sunburns, bathing vacations 
and solarium use). bAdditionally adjusted for body surface area (BSA) and smoking. cAdditionally adjusted for education. dAdditionally adjusted for BSA, 
smoking and education. eAdditionally adjusted for marital status and smoking. fOnly in parous women. gOnly in postmenopausal women. hOnly in parous 
postmenopausal women. iAnalysed as time-dependent.  
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Table 4. Reproductive factors and risk of melanoma by anatomical site: The NOWAC Study. 
 Head and neck Upper limbs Trunk Lower limbs 
 No. of 
cases 
 
HR (95% CI) 
No. of 
cases 
 
HRa (95% CI) 
No. of 
cases 
 
HRa (95% CI) 
No. of 
cases 
 
HRa(95% CI) 
p for 
heterogeneity 
Age at menarche, n = 162,881          
  ≤ 11 years 6 0.54 (0.23 – 1.27) 18 0.94 (0.56 – 1.58) 37 1.08 (0.74 – 1.56) 35 0.81 (0.56 – 1.18)  
  12 years 23 0.91 (0.54 – 1.53) 46 1.07 (0.73 – 1.56) 98 1.32 (1.00 – 1.73) 117 1.24 (0.97 – 1.59)  
  13 years 38 Ref. 64 Ref. 110 Ref. 138 Ref.  
  14 years 29 0.81 (0.50 – 1.31) 51 0.86 (0.60 – 1.25) 110 1.11 (0.85 – 1.44) 119 0.95 (0.75 – 1.22)  
  ≥ 15 years 16 0.56 (0.31 – 1.02) 37 0.81 (0.54 – 1.22) 85 1.16 (0.87 – 1.54) 88 0.96 (0.74 – 1.26)  
  Per year 112 0.94 (0.82 – 1.07) 216 0.93 (0.85 – 1.03) 440 1.00 (0.94 – 1.07) 497 0.98 (0.92 – 1.04) 0.63 
Menstrual cycle length during 
midlifeb, n = 47,880 
         
  < 25 days 8 2.01 (0.91 – 4.44) 7 0.66 (0.30 – 1.43) 14 0.65 (0.37 – 1.13) 29 1.12 (0.75 – 1.66)  
  25 – 30 days 26 Ref. 70 Ref. 138 Ref. 167 Ref.   
  > 30 days 0  5 1.31 (0.53 – 3.24) 10 1.33 (0.70 – 2.52) 4 0.43 (0.16 – 1.17)  
  Per day 34 0.94 (0.85 – 1.03) 82 1.03 (0.95 – 1.11) 162 1.07 (1.01 – 1.13) 200 0.99 (0.94 – 1.03) 0.07 
Parityc,i, n = 165,712          
  0 children 6 Ref. 17 Ref. 50 Ref. 46 Ref.  
  1 child 11 1.74 (0.64 – 4.73) 21 1.11 (0.59 – 2.11) 47 0.78 (0.52 – 1.16) 48 0.87 (0.58 – 1.30)  
  2 children 45 1.93 (0.82 – 4.53) 96 1.38 (0.82 – 2.31) 194 0.89 (0.65 – 1.22) 218 1.08 (0.78 – 1.48)  
  3 children 33 2.06 (0.86 – 4.95) 62 1.36 (0.79 – 2.34) 108 0.85 (0.60 – 1.19) 150 1.26 (0.91 – 1.77)  
  ≥ 4 children 17 2.11 (0.82 – 5.42) 24 1.13 (0.60 – 2.12) 50 1.02 (0.68 – 1.52) 45 0.98 (0.64 – 1.49)  
Per child 112 1.08 (0.94 – 1.25) 220 1.03 (0.93 – 1.15) 449 1.02 (0.94 – 1.11) 507 1.04 (0.96 – 1.12) 0.92 
Nulliparousc,i, n = 165,712          
  No 106 Ref. 203 Ref. 399 Ref. 461 Ref.  
  Yes 6 0.51 (0.22 – 1.16) 17 0.77 (0.47 – 1.26) 50 1.14 (0.85 – 1.54) 46 0.92 (0.68 – 1.25) 0.22 
Age at first birthc,f, n = 149,863          
  < 22 years 35 Ref. 48 Ref. 128 Ref. 145 Ref.  
  22 – 23 years 17 0.67 (0.37 – 1.20) 53 1.62 (1.09 – 2.40) 66 0.81 (0.60 – 1.09) 90 0.97 (0.74 – 1.26)  
  24 – 26 years 28 0.84 (0.50 – 1.41) 51 1.21 (0.80 – 1.82) 103 1.00 (0.77 – 1.32) 117 1.00 (0.77 – 1.29)  
  ≥ 27 years 26 0.73 (0.42 – 1.27) 51 1.26 (0.76 – 1.78) 102 0.97 (0.73 – 1.28) 109 0.90 (0.69 – 1.17)  
Per year 106 0.98 (0.94 – 1.03)  1.00 (0.96 – 1.03) 399 1.00 (0.97 – 1.02) 461 0.99 (0.96 – 1.01) 0.86 
Menopausal statusd,i, n = 165,712          
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  Pre 16 Ref. 22 Ref. 76 Ref. 97 Ref.  
  Post 96 0.36 (0.10 – 1.26) 198  1.70 (0.77 – 3.78) 373 0.54 (0.31 – 0.92) 409 1.08 (0.68 – 1.71) 0.04 
Age at last birthc,h, n = 127,350          
  < 26 years 23 Ref. 37 Ref. 79 Ref. 87 Ref.  
  26 – 28 years 14 0.57 (0.29 – 1.11) 41 1.09 (0.69 – 1.70) 73 0.98 (0.71 – 1.35) 83 1.00 (0.74 – 1.35)  
  29 – 32 years 31 0.87 (0.50 – 1.51) 52 1.00 (0.65 – 1.54) 91 0.96 (0.71 – 1.31) 101 0.95 (0.71 – 1.27)  
  ≥ 33 years 23 0.54 (0.30 – 0.99) 54 0.94 (0.60 – 1.45) 89 0.95 (0.69 – 1.30) 99 0.93 (0.69 – 1.26)  
  Per year 91 0.97 (0.93 – 1.02) 184 0.98 (0.95 – 1.01) 332 1.00 (0.98 – 1.02) 370 0.99 (0.97 – 1.01) 0.74 
Breastfeeding duratione,g, 
n = 85,406 
         
  0 months 8 1.78 (0.75 – 4.20) 9 1.09 (0.52 – 2.30) 11 0.83 (0.43 – 1.61) 19 1.35 (0.79 – 2.29)  
  1 – 4 months 14 1.31 (0.63 – 2.73) 17 0.79 (0.43 – 1.43) 34 0.98 (0.63 – 1.53) 35 0.94 (0.61 – 1.45)  
  5 – 9 months 15 Ref. 30 Ref. 45 Ref. 49 Ref.  
  10 – 16 months 9 0.57 (0.25 – 1.31) 31 1.01 (0.61 – 1.66) 55 1.24 (0.84 – 1.85) 62 1.27 (0.87 – 1.85)  
 ≥17 months 20 0.92 (0.47 – 1.81) 39 0.98 (0.60 – 1.58) 63 1.16 (0.79 – 1.71) 64 1.09 (0.75 – 1.59)  
 Per month 66 0.98 (0.96 – 1.01) 126 1.00 (0.98 – 1.01) 208 1.01 (1.00 – 1.02) 229 1.00 (0.99 – 1.01) 0.29 
Length of ovulatory lifeb,g, 
n = 142,611 
         
  Q1: < 33.5 years 22 1.10 (0.62 – 1.95) 42 0.80 (0.52 – 1.22) 78 0.82 (0.60 – 1.11) 111 1.07 (0.81 – 1.42)  
  Q2: 33.5 – 36.5 years 26 Ref. 47 Ref. 94 Ref. 96 Ref.  
  Q3: 36.6 – 38.4 years 19 1.13 (0.61 – 2.10)  43 1.17 (0.77 – 1.77) 65 0.78 (0.60 – 1.08) 82 1.00 (0.74 – 1.35)  
  Q4: ≥ 38.5 years 16 1.12 (0.58 – 2.16) 38 1.16 (0.75 – 1.80) 81 1.06 (0.78 – 1.44) 71 0.94 (0.68 – 1.28)  
  Per year 83 0.98 (0.94 – 1.03) 170 1.03 (0.99 – 1.07) 318 1.02 (0.99 – 1.05) 360 1.00 (0.97 – 1.02) 0.32 
aHazard ratios (HRs) and 95% confidence intervals (CIs)  from Cox regression with age as the time scale (age adjusted) and adjusted for residential ambient 
ultraviolet (UV) exposure, birth cohort, host pigmentation (hair color, skin color and large asymmetric nevi) and UV exposure (sunburns, bathing vacations 
and solarium use). bAdditionally adjusted for body surface area (BSA) and smoking. cAdditionally adjusted for education. dAdditionally adjusted for BSA, 
smoking and education. eAdditionally adjusted for marital status and smoking. fOnly in parous women. gOnly in postmenopausal women. hOnly in parous 
postmenopausal women. iAnalysed as time-dependent.  
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